v3.26.1
Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting [Abstract]    
Navacaprant (NMRA-140) program $ (93,204) $ (105,442)
M4 PAM programs (12,277) (11,041)
NMRA-511 program (8,097) (7,236)
Preclinical programs (10,987) (5,776)
Research and development personnel-related costs (36,052) (47,036)
General and administrative expense (60,091) (62,537)
Acquired in-process research and development (5,000) 0
Interest income 8,344 19,933
Interest expense (3,219)  
Other segment items (16,345) (24,652)
Net loss $ (236,928) $ (243,787)